Here's your US review and approval news for the week in brief: It didn't take the Food and Drug Administration long to approve the first novel drug of 2020 (and the new decade), with the honor going to Blueprint Medicines Corp.'s targeted gastrointestinal stromal tumor (GIST) drug Ayvakit (avapritinib).
A notable supplemental approval went to Merck & Co. Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?